[10-24]Tumor-Specific Nanoparticle Platforms for Improving Cancer Therapy

报告题目：Tumor-Specific Nanoparticle Platforms for Improving Cancer Therapy

报 告 人：Xiuling Lu，Ph.D.

     Department of Pharmaceutical Sciences

     University of Connecticut

报告时间：2016年10月24日（周一）14：00

报告地点：苏州大学药学院（二期云轩楼1323会议室）

报告人简介：

Xiuling Lu, Ph.D., an Assistant Professor of Pharmaceutics at the University of Connecticut received her Ph.D. in Biochemical Engineering from the Chinese Academy of Sciences in 2005. She joined the University of Kentucky as a Postdoctoral Scholar in 2006 and received a prestigious Benedict Cassen Post-Doctoral Fellowship Award from the Education and Research Foundation for the Society of Nuclear Medicine to work on dual imaging-therapeutic nanovectors in 2008. She continued this line of research as a Research Assistant Professor at the University of North Carolina at Chapel Hill from 2008 to 2011, and then joined the University of Connecticut School of Pharmacy in 2011. Dr. Lu’s research interests include nanoparticle-based drug delivery platforms for improving therapeutic indices of anti-cancer agents, image-guided drug delivery for optimizing cancer diagnosis and therapy, and neutron-activatable nanoparticles for radiation therapy. Dr. Lu has more than 50 publications and 7 patent applications. Her research is supported by NIH, American Cancer Society, FDA, NSF etc. The talk will focus on two of her major platform technologies utilizing multifunctional nanoparticles to achieve safer and more effective cancer treatment.